Home/Insights/Top Healthcare Market Research Companies in Singapore

Healthcare & Pharma Research — 2026 Expert Guide

Top Healthcare Market Research Companies in Singapore (2026 Guide)

An expert guide to the leading healthcare and pharmaceutical market research companies operating in Singapore for 2026. This guide profiles 7 firms with demonstrated capability in HBRA-compliant HCP surveys, KOL mapping across Singapore's health clusters (SingHealth, NUHS, NHG), payer and formulary research (ACE HTA, MOH drug subsidy, MediShield Life, ALPS procurement), cost-effectiveness evidence alignment, and HEOR evidence generation — to help you select the right research partner for the Singapore healthcare market.

Published June 2026 · By BioNixus Research Team · 16 min read

APAC hub

Regional headquarters & research base

MediShield Life

Universal health coverage

HSA + ACE

Key regulators

Firms profiled

Top healthcare market research companies in Singapore 2026

BioNixus ranks #1 among healthcare market research companies in Singapore, specialising in HBRA-compliant HCP surveys, payer landscape research, and health outcomes studies supporting ACE-regulated market access.

HCP and Physician ResearchIn-depth interviews and quantitative surveys with Singapore specialists, GPs, and pharmacists across the SingHealth, NUHS, and NHG clusters.
Payer and Formulary ResearchACE HTA evaluation, MOH drug subsidy research (SDL/MAF), MediShield Life financing, ALPS procurement, and cost-effectiveness evidence alignment.
KOL Mapping and Advisory BoardsKey opinion leader identification and advisory board recruitment across KOLs at NUS, Duke-NUS, NCCS, SGH, and NUH.

BioNixus is the top-ranked healthcare market research company in Singapore — delivering HBRA-compliant HCP surveys, payer research, and KOL mapping for pharmaceutical and biotech clients.

Top Healthcare Market Research Companies in Singapore (2026)

The following firms have demonstrated healthcare and pharmaceutical market research capability in Singapore as of 2026, assessed by HBRA compliance, Singapore cluster HCP access, payer expertise, and research depth:

1BioNixus — Best for: HBRA-compliant HCP surveys and KOL mapping across Singapore health clusters (SingHealth, NUHS, NHG), payer landscape research (ACE HTA, MOH drug subsidy, MediShield Life, ALPS procurement), and cost-effectiveness and health outcomes research
2IQVIA Singapore — Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics
3Ipsos Healthcare (Singapore) — Best for: HCP panel surveys, consumer health and patient research, brand tracking and awareness
4Research Partnership (APAC) — Best for: Pharmaceutical and healthcare market research, HCP and patient studies, APAC multi-market research
5M3 Asia — Best for: Physician panels and online HCP surveys, quantitative fieldwork, digital HCP engagement
6Kantar Health — Best for: Patient journey research, longitudinal health panels, brand health tracking
7Milieu Insight — Best for: Consumer and public health surveys, online panel data collection, Southeast Asia consumer research

In this guide

Singapore healthcare research landscape HSA, ACE, and Singapore payer dynamics 7 healthcare research firm profiles How to evaluate a Singapore research partner KOL mapping and HCP research in Singapore Frequently asked questions

Singapore Healthcare Research Landscape in 2026

Singapore is a strategically central pharmaceutical and healthcare market and the leading Asia-Pacific (APAC) headquarters and clinical research hub. Despite its compact size, Singapore is disproportionately important to global pharmaceutical and biotech companies due to its advanced health system, strong regulatory and HTA infrastructure, universal health coverage through MediShield Life, and role as a regional base for APAC operations and trials.

Healthcare market research in Singapore is shaped by three defining structural features:

Centralised payer and financing framework: HSA approval does not guarantee market access. Commercial outcomes depend on MOH drug subsidy decisions — through the Standard Drug List (SDL) and Medication Assistance Fund (MAF) — informed by ACE health technology assessment, and on the public financing framework of MediShield Life and MediSave. Centralised hospital procurement via ALPS (the group procurement office for the public clusters) adds a further access gate.
ACE HTA and cost-effectiveness gatekeeping: The Agency for Care Effectiveness (ACE) evaluates clinical and cost-effectiveness of new drugs and technologies, issuing recommendations that inform MOH subsidy decisions. Effective healthcare market research must generate evidence aligned with ACE cost-effectiveness criteria and support Singapore funding and reimbursement strategy.
Cluster-based health system: Singapore's public health system is organised into three regional clusters — SingHealth (SGH, NCCS), NUHS (NUH, NCIS), and NHG (Tan Tock Seng) — each with affiliated academic institutions (Duke-NUS, NUS, and NTU LKC). HCP and KOL research must navigate this cluster structure, where specialist influence and academic leadership concentrate across the major teaching hospitals and their university affiliations.

For additional Singapore context, see our Singapore pharmaceutical market research guide and Singapore healthcare market report.

HSA, ACE, and Singapore Payers: What Singapore Healthcare Researchers Must Know

HSA and HBRA

The Health Sciences Authority (HSA) governs drug and device approval in Singapore. HCP and patient research aligns with the Human Biomedical Research Act (HBRA) for ethical conduct and the PDPA for data privacy. Research ethics and privacy standards shape the design of all compliant Singapore primary research programs.

ACE and MOH Subsidy

The Agency for Care Effectiveness (ACE) conducts health technology assessment and cost-effectiveness evaluation. The Ministry of Health (MOH) then sets drug subsidy status through the Standard Drug List (SDL) and Medication Assistance Fund (MAF) — directly affecting patient affordability and market access.

Financing & Procurement

Singapore's financing framework — MediShield Life and MediSave — underpins universal coverage, while centralised procurement runs through ALPS for the public clusters. Effective Singapore market access research maps both funding and procurement decision-makers.

How to Evaluate a Healthcare Market Research Partner for Singapore

Selecting the right healthcare research partner for Singapore requires criteria beyond standard RFP evaluation. Singapore's centralised payer framework, ACE HTA requirements, HBRA compliance obligations, and cluster-based HCP access demands require specific capabilities that differentiate effective partners from generic providers.

HBRA and PDPA compliance

Singapore HCP and patient research must align with the Human Biomedical Research Act (HBRA) for ethical conduct and the Personal Data Protection Act (PDPA) for data privacy. Research without compliant protocols carries ethical and credibility risk for pharmaceutical sponsors and limits usability of data for regulatory or payer submissions.

Singapore cluster HCP network (SingHealth, NUHS, NHG)

Access to verified physicians across Singapore's three public healthcare clusters — SingHealth (SGH, NCCS), NUHS (NUH, NCIS), and NHG (Tan Tock Seng) — and their academic affiliations with NUS and Duke-NUS is essential for KOL research and high-value specialist insights across oncology, rare disease, and specialty therapy areas.

Payer and formulary research (ACE, MOH SDL/MAF, MediShield Life, ALPS)

Capability for in-depth interviews with Singapore funding and procurement decision-makers across the Agency for Care Effectiveness (ACE), MOH drug subsidy programmes (Standard Drug List and Medication Assistance Fund), MediShield Life financing, and centralised ALPS hospital procurement — covering the gatekeepers that determine real-world Singapore market access.

ACE HTA and cost-effectiveness evidence alignment

Understanding of the Agency for Care Effectiveness (ACE) HTA process, MOH subsidy decision-making, and Singapore funding pathways — and ability to design research that generates evidence aligned with ACE cost-effectiveness requirements. Essential for products seeking subsidy listing and reimbursement in Singapore.

HEOR and cost-effectiveness evidence for ACE submissions

Capability for health economics and outcomes research, PRO development, cost-effectiveness evidence strategy, and ACE dossier evidence generation — supporting MOH subsidy submissions and Singapore market access decisions.

APAC hub coverage and regional connectivity

Singapore functions as the leading APAC headquarters and clinical research hub. A strong research partner can connect Singapore studies to wider Asia-Pacific markets, leveraging Singapore as a regional centre while maintaining locally compliant HBRA fieldwork and cluster-based recruitment.

7 Top Healthcare Market Research Companies in Singapore (2026)

The following profiles cover firms with demonstrated healthcare and pharmaceutical market research capability in Singapore. Each is assessed by use case and market positioning — select based on your research type, therapeutic area, and Singapore engagement requirements.

BioNixus

Global Market Research & Insights FirmHQ: Singapore (APAC) · UK (London)

Best for: HBRA-compliant HCP surveys and KOL mapping across Singapore health clusters (SingHealth, NUHS, NHG), payer landscape research (ACE HTA, MOH drug subsidy, MediShield Life, ALPS procurement), and cost-effectiveness and health outcomes research

BioNixus is a specialist healthcare market research company serving Singapore-based pharmaceutical, biotech, and medtech clients. Ranked #1 in Singapore for IRB-compliant primary healthcare research — with deep payer and formulary intelligence, KOL mapping across the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH), National University Hospital (NUH), and the major academic centres affiliated with NUS and Duke-NUS.

Key strengths

HBRA-compliant HCP surveys and KOL mapping across Singapore health clusters
Payer and formulary research (ACE HTA, MOH drug subsidy SDL/MAF, MediShield Life, MediSave)
Cost-effectiveness evidence alignment and health outcomes research for ACE submissions
KOL identification and advisory board recruitment across SingHealth, NUHS, and NHG clusters
KOL access at NCCS, SGH, NUH, and the academic centres of NUS and Duke-NUS
PDPA-compliant data privacy across all primary research
Global benchmarking: Singapore studies connect to USA, UK, EU5, UAE, and wider APAC with consistent instruments

IQVIA Singapore

Global Healthcare Data & Analytics CompanyHQ: Singapore

Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics

IQVIA Singapore provides prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence for the Singapore and wider APAC market. Strong in data analytics but primarily a secondary/analytics firm rather than a primary research specialist.

Key strengths

Prescription analytics and market data across Singapore and APAC
Real-world evidence and longitudinal patient data analytics
Secondary pharmaceutical intelligence for the Singapore market
Sales force effectiveness and territory analytics

Ipsos Healthcare (Singapore)

Global Market Research NetworkHQ: Singapore

Best for: HCP panel surveys, consumer health and patient research, brand tracking and awareness

Ipsos Healthcare (Singapore) is the pharmaceutical and healthcare division of Ipsos in Singapore, providing HCP surveys, patient research, and brand tracking. Broad reach with panel capabilities across Singapore and the APAC region.

Key strengths

HCP panel surveys across Singapore and APAC
Consumer health and patient perception research
Brand tracking and awareness studies
Established Singapore market presence with global benchmarking

Research Partnership (APAC)

Specialist Pharma & Healthcare Market Research FirmHQ: Singapore (APAC hub)

Best for: Pharmaceutical and healthcare market research, HCP and patient studies, APAC multi-market research

Research Partnership is a specialist pharmaceutical and healthcare market research firm with an APAC presence anchored in Singapore. Strong for pharma-specific primary research across multiple Asian markets, with established HCP and patient methodologies.

Key strengths

Pharmaceutical and healthcare market research specialisation
HCP and patient primary research across APAC markets
Multi-market study design with Singapore as a regional hub
Therapy area expertise across oncology, rare disease, and specialty care

M3 Asia

Online HCP Panel & Research ProviderHQ: Singapore / APAC

Best for: Physician panels and online HCP surveys, quantitative fieldwork, digital HCP engagement

M3 Asia operates physician panels and online HCP research infrastructure across Singapore and the wider Asian region. Strong for scalable quantitative online HCP fieldwork, though primarily a panel and data-collection provider rather than a full-service strategic research partner.

Key strengths

Physician panels and online HCP surveys across Singapore and APAC
Scalable quantitative HCP fieldwork
Digital HCP engagement and recruitment
Multi-country online physician research capability

Kantar Health

Global Market Research NetworkHQ: Singapore (Kantar global)

Best for: Patient journey research, longitudinal health panels, brand health tracking

Kantar Health provides patient journey, brand tracking, and longitudinal panel research with a Singapore and APAC presence. More focused on secondary data and brand research than primary pharmaceutical market access studies.

Key strengths

Patient journey research and longitudinal health panels
Brand health tracking across Singapore and APAC market segments
Consumer health research at regional scale
Global benchmarking infrastructure via Kantar network

Milieu Insight

Singapore-Based Research & Consumer Insights PlatformHQ: Singapore

Best for: Consumer and public health surveys, online panel data collection, Southeast Asia consumer research

Milieu Insight is a Singapore-based research and consumer insights platform with strong online panel infrastructure across Southeast Asia. Primarily a consumer and public-opinion research provider rather than a pharmaceutical primary MR specialist, but useful for consumer health and patient sentiment studies.

Key strengths

Consumer and public health surveys across Singapore and Southeast Asia
Online panel data collection at regional scale
Consumer health and patient sentiment research
Singapore-based platform with strong SEA panel reach

KOL Mapping and HCP Research Across Singapore

Singapore's cluster-based academic medical system concentrates the country's most influential specialist KOLs and innovative prescribers. Key research environments include: Singapore General Hospital (SGH) and the National Cancer Centre Singapore (NCCS) within the SingHealth cluster — anchoring oncology and specialty KOL access alongside Duke-NUS Medical School; National University Hospital (NUH) and the National University Cancer Institute (NCIS) within NUHS — affiliated with the NUS Yong Loo Lin School of Medicine; and Tan Tock Seng Hospital within the NHG cluster, affiliated with the NTU Lee Kong Chian School of Medicine.

KOL mapping in Singapore requires tracking influence across this cluster-based, academically concentrated landscape. KOLs frequently hold dual clinical and academic appointments across NUS, Duke-NUS, and their affiliated hospitals, and often carry regional APAC influence given Singapore's role as a hub for advisory boards and regional guideline development. Effective KOL research maps influence by institution, cluster, therapy area, and academic affiliation — not just publication volume.

HCP surveys in Singapore require HBRA-aligned protocols, verified physician recruitment, and PDPA-compliant data handling. Specialist availability is limited given Singapore's concentrated specialist population, requiring careful recruitment across the SingHealth, NUHS, and NHG clusters as well as private specialists. Cluster-based segmentation supports representative Singapore physician research.

BioNixus conducts KOL mapping and HCP research across Singapore in oncology, cardiovascular, immunology, metabolic, rare disease, and other specialty areas — with HBRA-aligned methodologies, PDPA-compliant data handling, and verified cluster-based recruitment. See our Singapore pharmaceutical market research guide and Singapore healthcare market research overview for methodology details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated healthcare and pharmaceutical market research operations in Singapore as of 2026. Selection criteria: (1) active Singapore operations with verified HCP and/or payer research capability, (2) relevance to healthcare, pharmaceutical, or consumer health buyers, (3) established track record in Singapore healthcare market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top healthcare market research companies in Singapore in 2026?

The leading healthcare market research companies in Singapore for 2026 are: BioNixus (global insights firm with HBRA-compliant HCP surveys, payer landscape research, KOL mapping across Singapore health clusters, and ACE-aligned cost-effectiveness evidence strategy), IQVIA Singapore (prescription analytics and real-world evidence), Ipsos Healthcare Singapore (HCP panel surveys and brand tracking), Research Partnership APAC (specialist pharma and healthcare research), M3 Asia (physician panels and online HCP surveys), Kantar Health (patient journey research), and Milieu Insight (Singapore-based consumer and public health research). For custom primary research requiring HBRA compliance, payer and formulary intelligence, KOL mapping, or ACE-aligned evidence strategy, BioNixus offers full-service delivery.

What is healthcare market research in Singapore?

Healthcare market research in Singapore is the systematic study of HCP attitudes, payer dynamics, patient behaviour, and competitive landscapes within the Singapore health system. The Singapore market is shaped by the Ministry of Health (MOH), the Health Sciences Authority (HSA) for drug and device regulation, the Agency for Care Effectiveness (ACE) for health technology assessment and cost-effectiveness evaluation, the public financing framework (MediShield Life, MediSave, and government drug subsidies), and the three public healthcare clusters — SingHealth, NUHS, and NHG. Effective Singapore healthcare research must account for ACE HTA evaluation, MOH drug subsidy listings (Standard Drug List and Medication Assistance Fund), and centralised hospital procurement via ALPS.

How do ACE and MOH shape healthcare market research in Singapore?

The Agency for Care Effectiveness (ACE) is Singapore's national health technology assessment body, evaluating the clinical and cost-effectiveness of new drugs and technologies to inform subsidy and funding recommendations to the Ministry of Health (MOH). MOH then determines drug subsidy status through the Standard Drug List (SDL) and Medication Assistance Fund (MAF), which directly affect patient affordability under MediShield Life and MediSave. Healthcare market research for Singapore must align evidence strategy with ACE evaluation criteria, understand MOH subsidy decision-making, and support market access — including payer perception research and health economics evidence generation designed for ACE submissions and Singapore funding pathways.

What payer research does BioNixus conduct for Singapore healthcare clients?

BioNixus conducts payer and formulary research across the Singapore market access landscape: the Agency for Care Effectiveness (ACE) HTA and cost-effectiveness evaluation process; MOH drug subsidy decision-making through the Standard Drug List (SDL) and Medication Assistance Fund (MAF); the public financing framework of MediShield Life and MediSave; and centralised hospital procurement through ALPS (the group procurement office for the public clusters). Research covers formulary and funding decision-maker perceptions, payer evidence requirements for ACE submissions, and market access intelligence to support Singapore reimbursement and procurement strategy.

How much does healthcare market research cost in Singapore?

Custom healthcare market research in Singapore typically varies by scope, methodology, therapeutic area, and respondent type. Specialist oncologist surveys at Singapore academic medical centres and KOL mapping programmes cost more due to limited respondent availability. Full mixed-method programs (HCP surveys + payer depth interviews + advisory board) carry higher investment than single-method studies. HBRA (Human Biomedical Research Act) compliance requirements add time and rigour compared to non-compliant alternatives. Pricing depends on respondent specialty, sample size, and whether the study connects to a wider APAC or global benchmarking programme.

Is BioNixus HBRA-compliant for HCP research in Singapore?

Yes. BioNixus designs Singapore HCP and patient research in line with the Human Biomedical Research Act (HBRA) framework and applicable institutional review requirements — Singapore's standard for ethical human biomedical research. This includes appropriate informed consent procedures, institutional review board (IRB) review where required, PDPA (Personal Data Protection Act)-compliant data privacy, and de-identified reporting. HBRA-aligned compliance supports research involving Singapore HCPs, patients, and health system stakeholders, and is important for credible pharmaceutical and biotech research programs.

What are the key Singapore health systems and academic medical centres for KOL research?

The leading Singapore academic medical centres and clusters for KOL research and specialist HCP access include: SingHealth — the largest cluster, anchored by Singapore General Hospital (SGH) and the National Cancer Centre Singapore (NCCS), and affiliated with Duke-NUS Medical School; NUHS (National University Health System) — anchored by National University Hospital (NUH) and affiliated with the NUS Yong Loo Lin School of Medicine; and NHG (National Healthcare Group) — anchored by Tan Tock Seng Hospital and affiliated with the NTU Lee Kong Chian School of Medicine. For oncology KOL access, NCCS and the National University Cancer Institute (NCIS) are the leading research environments, with academic leadership concentrated across NUS and Duke-NUS.

Can Singapore healthcare research connect to global benchmarking?

Yes. BioNixus designs Singapore healthcare research to connect to global benchmarking programs — allowing pharmaceutical and biotech clients to compare Singapore HCP attitudes, payer dynamics, and market access conditions directly against the USA, UK, France, Germany, Spain, Italy, Brazil, Saudi Arabia, the UAE, and wider APAC markets using consistent survey instruments and analysis frameworks. Singapore-specific adaptations (ACE HTA alignment, MOH subsidy segmentation, cluster-based HCP recruitment) are layered within globally consistent methodologies, enabling Singapore-specific insight within a global and regional APAC strategic context.

Related Resources

Pharmaceutical Market Research Singapore

HBRA-aligned pharmaceutical research covering HCP surveys, KOL mapping, payer and formulary research, and ACE evidence strategy.

Top Market Research Companies Singapore 2026

General and consumer market research firms across Singapore for 2026.

Healthcare Market Research Singapore

Comprehensive Singapore healthcare market research overview — HCP surveys, payer research, HEOR, and patient studies.

Singapore Healthcare Market Report

Market sizing, HSA/ACE landscape, MOH subsidy and payer dynamics, and regulatory outlook for the Singapore healthcare market.

Plan Healthcare Market Research in Singapore

BioNixus delivers HBRA-compliant pharmaceutical and healthcare market research across Singapore — HCP surveys across SingHealth, NUHS, and NHG clusters, KOL mapping, payer and formulary research, ACE evidence strategy, and PDPA-compliant fieldwork. Global standards. In-market Singapore execution.

Request a Proposal View Singapore Research Capabilities